Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2022-10-10 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
Regulatory Filings Classification · 1% confidence The document is a press release dated October 10th, 2022, announcing that AB Science has received initial authorizations from regulatory agencies (ANSM, AEMPS, EOF) to initiate a confirmatory Phase 3 clinical study (AB21004) for masitinib in Alzheimer's Disease. It details the study design, endpoints, compares the drug mechanism to competitors, and provides commentary from key personnel. It also summarizes results from a previous Phase 2B/3 study (AB09004). This content is characteristic of an announcement regarding clinical trial progress and scientific updates, which is typically disseminated via an Earnings Release (ER) or a general Regulatory Filing (RNS) if no other specific category fits. Since it is a detailed announcement of clinical trial progress and scientific findings, rather than just a brief financial highlight (ER) or a general regulatory notice (RNS), it most closely aligns with an announcement that would accompany or precede a more formal report, but given the options, it functions as a significant corporate update. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a specific financial filing like DEF 14A or DIV. It is a detailed corporate communication about R&D progress. In the context of the provided definitions, this type of detailed scientific/clinical update, often released outside of standard quarterly reporting cycles, is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing trial initiation and prior results, RNS serves as the most appropriate general regulatory/corporate announcement category when specific R&D update codes are missing. However, given the depth of the scientific and clinical data presented, it is a substantial piece of information intended for investors. Since it is not a formal financial report, nor a management discussion, nor a proxy statement, RNS is the best fit as a general regulatory announcement.
2022-10-10 English
AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has received the first regulatory authorizations (from ANSM, AEMPS, EOF) to initiate a confirmatory Phase 3 clinical study (AB21004) for Masitinib in Alzheimer's disease. It details the study design, mechanism of action, and references prior Phase 2B/3 results (AB09004). This type of announcement, detailing significant operational or clinical trial progress via a press release, is characteristic of an announcement rather than a formal, comprehensive regulatory report like a 10-K or IR. Since it is a press release announcing clinical trial progress and regulatory milestones, it fits best under the general category for regulatory announcements or news releases that don't fit a more specific financial report category. Given the options, it is a significant corporate announcement. It is not a formal Earnings Release (ER) as it focuses on clinical trials, nor is it a Management Discussion & Analysis (MDA). It is a general corporate update/announcement. The closest fit among the provided codes for a significant, non-financial-statement corporate update released via press release is often 'RNS' (Regulatory Filings/General Regulatory Announcements) or potentially 'LTR' if it were focused on legal proceedings, but here it is about clinical development. Since it is a press release announcing regulatory/clinical progress, 'RNS' serves as the best general regulatory/news announcement category when specific codes like 'ER' or 'IR' do not apply to the content type (which is a press release, not the full report). However, given the focus on clinical development and regulatory milestones, it is a key piece of investor information. Since it is not a formal financial report (10-K, IR, ER, MRQ), and it's not a presentation (IP), the most appropriate general regulatory/news category is RNS.
2022-10-10 French
AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2022, containing detailed consolidated financial statements (income statement, balance sheet), management's analysis of financial results, and operational updates. It is not a mere announcement of a report (RPA) as it contains the actual financial data and tables. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year. H1 2022
2022-09-30 English
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2022 et présente un point sur ses activités
Earnings Release Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces "RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2022" (Financial Results for the First Half of 2022). It contains detailed consolidated financial elements for the first semester (H1) ending June 30, 2022, including income statement and balance sheet data presented in tables, alongside clinical development updates. This structure—a press release summarizing period-specific financial performance and key operational events—is the hallmark of an Earnings Release (ER). It is not the full, comprehensive Annual Report (10-K) or a standalone Audit Report (AR). Since it provides the initial announcement of periodical financial results, the correct classification is ER. H1 2022
2022-09-30 French
Rapport financier semestriel 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Half-Year Financial Report) for AB Science S.A. as of June 30, 2022. It includes a formal declaration by the CEO, a detailed management report on activities, and condensed financial statements (income statement, operating results, etc.). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H2 2022
2022-09-30 French
AB Science - Recommandation favorable du comité indépendant de revue des données de poursuivre l’étude de Phase 2 évaluant l’activité antivirale du masitinib dans le traitement du Covid-19
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and is dated September 14, 2022. It announces a positive recommendation from an Independent Data Monitoring Committee (IDMC) to continue a Phase 2 clinical study evaluating Masitinib for COVID-19 treatment. This type of announcement, detailing clinical trial progress, management decisions, or operational updates via a press release format, does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement regarding R&D progress. Since it is not a formal regulatory filing (like a 10-K or 8-K equivalent in the US context, which would map to RNS if no other category fits), and it is not a management change (MANG), dividend (DIV), or earnings release (ER), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is the fallback category, Regulatory Filings (RNS), as press releases often serve as the initial public disclosure mechanism for material, non-financial events.
2022-09-14 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.